
Press release: Sequana Medical announces 2024 Full Year Results and 2025 Outlook
Sequana Medical announces 2024 Full Year Results and 2025 Outlook alfapump® – US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial launch planned for mid Q3 2025 DSR® – Publication of RED …